1. Home
  2. GGG vs VTRS Comparison

GGG vs VTRS Comparison

Compare GGG & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GGG
  • VTRS
  • Stock Information
  • Founded
  • GGG 1926
  • VTRS 1961
  • Country
  • GGG United States
  • VTRS United States
  • Employees
  • GGG N/A
  • VTRS N/A
  • Industry
  • GGG Fluid Controls
  • VTRS Medicinal Chemicals and Botanical Products
  • Sector
  • GGG Industrials
  • VTRS Health Care
  • Exchange
  • GGG Nasdaq
  • VTRS Nasdaq
  • Market Cap
  • GGG 13.3B
  • VTRS 11.1B
  • IPO Year
  • GGG N/A
  • VTRS N/A
  • Fundamental
  • Price
  • GGG $82.20
  • VTRS $10.17
  • Analyst Decision
  • GGG Buy
  • VTRS Hold
  • Analyst Count
  • GGG 2
  • VTRS 6
  • Target Price
  • GGG $94.00
  • VTRS $11.17
  • AVG Volume (30 Days)
  • GGG 635.7K
  • VTRS 7.5M
  • Earning Date
  • GGG 10-22-2025
  • VTRS 11-06-2025
  • Dividend Yield
  • GGG 1.34%
  • VTRS 4.71%
  • EPS Growth
  • GGG N/A
  • VTRS N/A
  • EPS
  • GGG 2.82
  • VTRS N/A
  • Revenue
  • GGG $2,167,974,000.00
  • VTRS $14,115,700,000.00
  • Revenue This Year
  • GGG $7.32
  • VTRS N/A
  • Revenue Next Year
  • GGG $4.19
  • VTRS $1.69
  • P/E Ratio
  • GGG $29.13
  • VTRS N/A
  • Revenue Growth
  • GGG 0.75
  • VTRS N/A
  • 52 Week Low
  • GGG $72.06
  • VTRS $6.85
  • 52 Week High
  • GGG $92.86
  • VTRS $13.55
  • Technical
  • Relative Strength Index (RSI)
  • GGG 43.01
  • VTRS 57.18
  • Support Level
  • GGG $81.13
  • VTRS $9.69
  • Resistance Level
  • GGG $82.82
  • VTRS $10.26
  • Average True Range (ATR)
  • GGG 1.36
  • VTRS 0.24
  • MACD
  • GGG -0.16
  • VTRS 0.03
  • Stochastic Oscillator
  • GGG 41.21
  • VTRS 74.17

About GGG Graco Inc.

Graco manufactures equipment used for managing fluids, coatings, and adhesives, specializing in difficult-to-handle materials. Graco's business is organized into three segments: industrial, process, and contractor. The Minnesota-based firm serves a wide range of end markets, including industrial, automotive, and construction, and its broad array of products include pumps, valves, meters, sprayers, and equipment used to apply coatings, sealants, and adhesives. The firm generated roughly $2.1 billion in sales in 2024.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: